Тематический план
- Cancer therapy
Cancer therapy
Today, cancer therapy is based primarily on chemotherapy and radiation, both of which have well-established side effects. Chemotherapy drugs typically kill not only cancer cells but also normal cells, and administration of bolus doses of these strong drugs can result in unpredictable side effects. One way of generating effective molecular probes to differentiate diseased cells is to use aptamers, that are capable of identifying molecular level differences between a healthy cell and a diseased cell
Aptamer−drug conjugates (ApDCs) have been developed to exploit aptamer-based targeted drug delivery. Current ApDC technologies largely rely on the noncovalent association of drug and specific DNA sequences,or complicated and less efficient organic synthesis.These technologies suffer from complicated preparation, low controllability of site-specific drug conjugation on vehicles, low synthesis yield in some cases, low drug loading capacity and the accompanying high cost and low spatiotemporal controllability in drug release
Nucleolin Aptamer-Paclitaxel Conjugate - Aptamers in Cancer therapy
- Thrombin Binding Aptamers
Thrombin Binding Aptamers
Thrombin is a serine protease that plays a crucial role in hemostasis, fibrinolysis, cell proliferation, and migration. Thrombin binding aptamer (TBA) is able to inhibit the activity of thrombin molecule via binding to its exosite I
- Тема 3
Тема 3